Business
MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report
Global expansion as MYND executes non-binding MOU with German based Oxygen Handel. Vancouver, Br...
About this update from Mynd Life Sciences Inc
[{"type":"text","content":"MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status ReportGlobal expansion as MYND executes non-binding MOU with German based Oxygen Handel.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (\"MYND\" or the \"Company\"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced it has entered into a non-binding memorandum of understanding (\"MOU\") with Oxygen Handel GmbH (O2 Handel).Oxygen Handel is a privately held science-based, research-driven pharmaceutical company consisting of carefully selected, highly qualified teams of experts with many years of experience in the successful drug development and biotechnology campaigns. Oxygen Handel is a fully integrated pharmaceutical company from drug discovery to development and marketing. In cooperation with leading research, healthcare or logistics companies, O2 Handel implements complex ideas and makes products accessible to patients across the European Union. The proposed collaboration is a strategic fit for both organizations as existing O2 Handel shareholders gain access to four (4) global provisional patents, public stock market liquidity, the Company's investment into research and development and the Company's biomarker research and diagnostic capabilities. Oxygen Handel will play a vital role in facilitating clinical partnerships to co-develop MYND's patented anti-inflammatory biomarker and non-hallucinogenic Psilocybin analog throughout the European Market.MYND's business strategy will remain consistent in translating innovative research approaches, with a strong focus on scientific excellence, into safe and effective neuro-pharmaceutical treatments and diagnostic capabilities for Central Nervous System diseases. \"We are very excited to create a dynamic partnership with Oxygen Handel and believe the combination of their intellectual assets and global breadth will stimulate long-term growth for the MYND shareholders,\" stated MYND CEO Dr. Lyle Oberg. Oxygen Handel VP for R&D, Dr. Bogdan Tamba states, \"After reviewing the various components of MYND's intellectual property, it's our opinion that the partnered entity is positioned uniquely in the biopha...